NIFTY 50

Getting ‘voluntary action indicated’ status for Malaysian unit a key development, says Biocon’s Kiran Mazumdar Shaw

Updated : April 01, 2020 11:16 AM IST

Post COVID-19, there will be a huge effort to bring down healthcare costs and biosimilars are certainly going to be extremely important in this effort.
Insulin therapies are going to play a key role in cost cutting and biosimilar glargine, insulins and others are going to be extremely important.

You May Also Like

Live TV